Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6

2013 ◽  
Vol 44 ◽  
pp. 49-60 ◽  
Author(s):  
Edith Hintermann ◽  
Janine Ehser ◽  
Monika Bayer ◽  
Josef M. Pfeilschifter ◽  
Urs Christen
2013 ◽  
Vol 42 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Doo-Yeoun Cho ◽  
Soo Hyeon Bae ◽  
Joeng Kee Lee ◽  
Yang Weon Kim ◽  
Bom-Taeck Kim ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 416-423
Author(s):  
Miaoran Ning ◽  
Julio D. Duarte ◽  
Faith Stevison ◽  
Nina Isoherranen ◽  
Leah H. Rubin ◽  
...  

PROTEOMICS ◽  
2009 ◽  
Vol 9 (9) ◽  
pp. 2313-2323 ◽  
Author(s):  
Elmar Langenfeld ◽  
Ulrich M. Zanger ◽  
Klaus Jung ◽  
Helmut E. Meyer ◽  
Katrin Marcus

FEBS Journal ◽  
2009 ◽  
Vol 276 (13) ◽  
pp. 3440-3453 ◽  
Author(s):  
Michelle Cook Sangar ◽  
Hindupur K. Anandatheerthavarada ◽  
Weigang Tang ◽  
Subbuswamy K. Prabu ◽  
Martha V. Martin ◽  
...  

2006 ◽  
Vol 1 (1) ◽  
pp. 1934578X0600100 ◽  
Author(s):  
Subehan ◽  
Tepy Usia ◽  
Shigetoshi Kadota ◽  
Yasuhiro Tezuka

Drug–herb interaction through inhibition of cytochrome P450 alters the pharmacological response and/or toxicities of drug used concomitantly. In our screening, Piper nigrum L. was observed to inhibit cytochrome P450 2D6 (CYP2D6) in human liver microsomes. Thus, the MeOH extract of this plant was investigated for their chemical constituents and 19 alkamides including a new pipercyclobutanamide were isolated. Their structures were elucidated on the basis of spectroscopic analyses. The isolated compounds were tested for their inhibition on human liver microsomal dextromethorphan O-demethylation activity, a selective marker for CYP2D6, and pipercyclobutanamide A (17) showed the most potent inhibition with an IC50 value of 0.34 μM. The result demonstrated the potential of drug–alkamides interaction on concomitant consume of white pepper with the drugs being metabolized by CYP2D6.


Author(s):  
Ingolf Cascorbi

The landmark paper discussed in this chapter is ‘Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)’, published by Dayer et al. in 1988. Codeine is an old but frequently prescribed drug used for the treatment of mild-to-moderate pain. However, its use is nowadays restricted after observations of partly fatal respiratory repression in children. Codeine itself exhibits no analgesic effect, but is partly activated by O-demethylation to morphine by cytochrome P450 2D6 (CYP2D6). The identification of the polymorphic CYP2D6 as the enzyme responsible for activation was achieved by Dayer et al. in 1998 and was an important milestone contributing to the widely observed inter-individual differences of drug action and side effects of codeine. Translating the pharmacogenetics of codeine into clinical practice is currently underway in clinical trials, to identify ineffective analgesics and, in particular, avoid severe adverse events.


2013 ◽  
Vol 51 (01) ◽  
Author(s):  
E Hintermann ◽  
J Ehser ◽  
M Bayer ◽  
J Pfeilschifter ◽  
U Christen

Sign in / Sign up

Export Citation Format

Share Document